A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
A phase 2 trial of T3011 in bladder & urothelial cancer, run by ImmVira Pharma Co. Ltd, now recruiting.
Overview
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC is a phase 2 interventional study registered as NCT06971614 by ImmVira Pharma Co. Ltd, with 160 participants planned, started 2025-06-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: T3011.
Similar pages
not linked directly; found by shared links- TrialA Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Shares ImmVira Pharma and the tag pipeline.
- TrialA Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva
Shares ImmVira Pharma, T3011.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialSafety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Shares Bladder & urothelial cancer and the tag pipeline.